Do analysts rate TTRX or NTRB?

Turn Therapeutics presently has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Turn Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turn Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.50 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to TTRX or NTRB?

In the previous week, Nutriband had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Nutriband and 2 mentions for Turn Therapeutics. Nutriband's average media sentiment score of -0.10 beat Turn Therapeutics' score of -0.18 indicating that Nutriband is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NTRB or FENC?

Adherex Technologies has a consensus price target of $17.00, suggesting a potential upside of 66.67%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to NTRB or FENC?

In the previous week, Nutriband had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Nutriband and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat Nutriband's score of -0.10 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENTA or NTRB?

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 5 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.15 beat Nutriband's score of -0.10 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NTRB or BIOA?

BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 453.27%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Is NTRB or BIOA more profitable?

Nutriband has a net margin of -430.35% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -430.35% -109.07% -95.54% BioAge Labs -912.26% -28.99% -27.09%

Does the media refer more to NTRB or BIOA?

In the previous week, Nutriband had 1 more articles in the media than BioAge Labs. MarketBeat recorded 5 mentions for Nutriband and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat Nutriband's score of -0.10 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VNDA or NTRB?

Vanda Pharmaceuticals currently has a consensus target price of $13.08, indicating a potential upside of 182.58%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor VNDA or NTRB?

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Nutriband. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 5 mentions for Nutriband. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Nutriband's score of -0.10 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Nutriband (NTRB) Competitors

$7.28 -0.08 (-1.09%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.43 +0.15 (+2.02%)

As of 10/2/2026 07:57 PM Eastern

Compare

NTRB vs. TTRX, FENC, ENTA, BIOA, and VNDA

Should you buy Nutriband stock or one of its competitors? Nutriband's main competitors and comparable companies include Turn Therapeutics (TTRX), Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), BioAge Labs (BIOA), and Vanda Pharmaceuticals (VNDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nutriband compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Turn Therapeutics has higher earnings, but lower revenue than Nutriband. Turn Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A

19.7% of Nutriband shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Turn Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Nutriband	-430.35%	-109.07%	-95.54%

In the previous week, Nutriband had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Nutriband and 2 mentions for Turn Therapeutics. Nutriband's average media sentiment score of -0.10 beat Turn Therapeutics' score of -0.18 indicating that Nutriband is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics presently has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Turn Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Turn Therapeutics beats Nutriband on 8 of the 15 factors compared between the two stocks.

How does Nutriband compare to Adherex Technologies?

Nutriband (NASDAQ:NTRB) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

19.7% of Nutriband shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A
Adherex Technologies	$44.64M	8.03	-$9.74M	-$0.13	N/A

Nutriband has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Adherex Technologies has a consensus price target of $17.00, suggesting a potential upside of 66.67%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adherex Technologies has a net margin of -6.09% compared to Nutriband's net margin of -430.35%. Adherex Technologies' return on equity of -5.71% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Adherex Technologies	-6.09%	-5.71%	-2.37%

In the previous week, Nutriband had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Nutriband and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat Nutriband's score of -0.10 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adherex Technologies beats Nutriband on 10 of the 16 factors compared between the two stocks.

How does Nutriband compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Nutriband has lower revenue, but higher earnings than Enanta Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.78	-$81.89M	-$2.41	N/A
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 5 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.15 beat Nutriband's score of -0.10 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals has a net margin of -96.89% compared to Nutriband's net margin of -430.35%. Enanta Pharmaceuticals' return on equity of -61.84% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Nutriband	-430.35%	-109.07%	-95.54%

Enanta Pharmaceuticals currently has a consensus target price of $19.00, indicating a potential upside of 46.60%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Enanta Pharmaceuticals beats Nutriband on 10 of the 15 factors compared between the two stocks.

How does Nutriband compare to BioAge Labs?

Nutriband (NASDAQ:NTRB) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Nutriband had 1 more articles in the media than BioAge Labs. MarketBeat recorded 5 mentions for Nutriband and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat Nutriband's score of -0.10 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nutriband has a net margin of -430.35% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
BioAge Labs	-912.26%	-28.99%	-27.09%

BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 453.27%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

19.7% of Nutriband shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 17.6% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nutriband has higher earnings, but lower revenue than BioAge Labs. Nutriband is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A
BioAge Labs	$8.99M	33.75	-$80.61M	-$2.38	N/A

Nutriband has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

Nutriband and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does Nutriband compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vanda Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Nutriband. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 5 mentions for Nutriband. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat Nutriband's score of -0.10 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vanda Pharmaceuticals currently has a consensus target price of $13.08, indicating a potential upside of 182.58%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nutriband has lower revenue, but higher earnings than Vanda Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.30	-$220.47M	-$4.63	N/A
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A

Vanda Pharmaceuticals has a net margin of -127.41% compared to Nutriband's net margin of -430.35%. Vanda Pharmaceuticals' return on equity of -49.81% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Nutriband	-430.35%	-109.07%	-95.54%

Summary

Vanda Pharmaceuticals beats Nutriband on 11 of the 16 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRB vs. The Competition

Export

Metric	Nutriband	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$88.50M	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-13.74	802.26	274.71	26.04
Price / Sales	43.39	940.01	656.47	105.79
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	16.55	10.52	10.93	6.31
Net Income	-$8.23M	$2.86B	$3.51B	$362.16M
7 Day Performance	-9.00%	-1.58%	-2.00%	-1.66%
1 Month Performance	21.94%	-5.55%	-6.19%	-4.68%
1 Year Performance	-2.02%	-2.19%	8.03%	1.57%

Nutriband Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRB Nutriband	0.6323 of 5 stars	$7.28 -1.1%	N/A	-2.0%	$88.50M	$2.04M	N/A	3	News Coverage
TTRX Turn Therapeutics	1.7981 of 5 stars	$13.41 +2.8%	$9.00 -32.9%	N/A	$388.44M	N/A	N/A	2
FENC Adherex Technologies	3.9747 of 5 stars	$10.80 -1.4%	$17.00 +57.4%	+3.2%	$383.89M	$59.22M	N/A	35	Gap Down
ENTA Enanta Pharmaceuticals	1.7587 of 5 stars	$12.64 +0.2%	$19.25 +52.3%	+25.5%	$367.42M	$65.32M	N/A	120	News Coverage Analyst Upgrade
BIOA BioAge Labs	3.0661 of 5 stars	$7.14 -0.6%	$36.57 +412.2%	+17.8%	$329.54M	$8.99M	N/A	62	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRB) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutriband (NTRB) Competitors

NTRB vs. TTRX, FENC, ENTA, BIOA, and VNDA

How does Nutriband compare to Turn Therapeutics?

Summary

How does Nutriband compare to Adherex Technologies?

Summary

How does Nutriband compare to Enanta Pharmaceuticals?

Summary

How does Nutriband compare to BioAge Labs?

Summary

How does Nutriband compare to Vanda Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutriband (NTRB) Competitors

NTRB vs. TTRX, FENC, ENTA, BIOA, and VNDA

How does Nutriband compare to Turn Therapeutics?

Which has higher valuation and earnings, TTRX or NTRB?

Do institutionals and insiders believe in TTRX or NTRB?

Is TTRX or NTRB more profitable?

Does the media refer more to TTRX or NTRB?

Do analysts rate TTRX or NTRB?

Summary

How does Nutriband compare to Adherex Technologies?

Do institutionals & insiders hold more shares of NTRB or FENC?

Which has stronger valuation & earnings, NTRB or FENC?

Which has more volatility and risk, NTRB or FENC?

Do analysts prefer NTRB or FENC?

Is NTRB or FENC more profitable?

Does the media refer more to NTRB or FENC?

Summary

How does Nutriband compare to Enanta Pharmaceuticals?

Which has preferable valuation and earnings, ENTA or NTRB?

Do institutionals and insiders have more ownership in ENTA or NTRB?

Which has more volatility and risk, ENTA or NTRB?

Does the media prefer ENTA or NTRB?

Is ENTA or NTRB more profitable?

Do analysts recommend ENTA or NTRB?

Summary

How does Nutriband compare to BioAge Labs?

Does the media refer more to NTRB or BIOA?

Is NTRB or BIOA more profitable?

Do analysts recommend NTRB or BIOA?

Do institutionals and insiders hold more shares of NTRB or BIOA?

Which has stronger valuation and earnings, NTRB or BIOA?

Which has more volatility and risk, NTRB or BIOA?

Summary

How does Nutriband compare to Vanda Pharmaceuticals?

Do institutionals & insiders have more ownership in VNDA or NTRB?

Which has more volatility & risk, VNDA or NTRB?

Does the media favor VNDA or NTRB?

Do analysts prefer VNDA or NTRB?

Which has preferable valuation and earnings, VNDA or NTRB?

Is VNDA or NTRB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools